Benactyzine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
302-40-9  Y |
| PubChem (CID) | 9330 |
| DrugBank |
DB09023  N |
| ChemSpider |
8966 Y |
| UNII |
595EG71R3F Y |
| KEGG |
D07498 Y |
| ChEMBL |
CHEMBL70352 Y |
| Chemical and physical data | |
| Formula | C20H25NO3 |
| Molar mass | 327.417 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| NY (what is this?) (verify) | |
Benactyzine is an anticholinergic drug that was used as an antidepressant in the treatment of depression and associated anxiety before it was pulled from the U.S. market by the FDA due to its ineffectiveness.[1]
Its use for these indications was limited by side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects.[1]
Brand names have included: Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence when combined with meprobamate with the medication no longer available it is not clinical important.[2]
History
Benactyzine was brought to market in the US in 1957 by Merck under the tradename, Suavitil.[3]
References
- 1 2 Shorter, E., Looking backwards: a possible new path for drug discovery in psychopharmacology. Nat Rev Drug Discov 2002, 1 (12), 1003–1006.
- ↑ DeBattista, Alan F. Schatzberg, Jonathan O. Cole, Charles (2010). Manual of clinical psychopharmacology (7th ed.). Washington, DC: American Psychiatric Pub. p. 423. ISBN 978-1-58562-377-8.
- ↑ Smith, Mickey C., PhD. Principles of Pharmaceutical Marketing, Third Edition. 3rd ed. New York: Routledge, 2013. Print. ISBN 978-1-317-94071-5
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the 6/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.